MarketScreener Strategies Veracyte, Inc.
Equities
VCYT
US92337F1075
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.08 USD | -0.63% |
|
+4.79% | -18.68% |
| Apr. 13 | Jefferies Initiates Veracyte at Buy With $45 Price Target | MT |
| Mar. 16 | Veracyte names Kevin Haas as chief development and technology officer | RE |
MarketScreener Strategies
Search
No results for this search
- Stock Market
- Equities
- VCYT Stock
- News Veracyte, Inc.
- MarketScreener Strategies
Select your edition
All financial news and data tailored to specific country editions
